Screener
NewAmsterdam Pharma Company NAMS Liabilities
Liabilities at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: NewAmsterdam Pharma Company’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333824
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Derivative warrant liabilities | 54,452 | 57,272 |
| Total current liabilities | 72,974 | 85,787 |
| Lease liability, net of current portion | 56 | 66 |
| Total liabilities | 73,030 | 85,853 |
| Commitments and contingencies (Note 12) | ||
| Shareholders' Equity: | ||
| Ordinary shares, €0.12 par value; 400,000,000 shares authorized; 117,651,697 and 114,399,326 shares issued and outstanding as at June 30, 2026 and December 31, 2025, respectively | 14,735 | 14,278 |
| Additional paid-in capital | 1,487,792 | 1,426,750 |
Item 1. Financial Statements.
FAQ
- What is NewAmsterdam Pharma Company's liabilities?
- NewAmsterdam Pharma Company (NAMS) reported liabilities of $73.03M in Q2 2026.
- How has NewAmsterdam Pharma Company's liabilities changed year-over-year?
- NewAmsterdam Pharma Company's liabilities increased by 99.5% year-over-year, from $36.62M to $73.03M.
- What is the long-term trend for NewAmsterdam Pharma Company's liabilities?
- Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's liabilities has grown at a 21.0% compound annual growth rate (CAGR), from $48.43M to $85.85M.
- What does liabilities mean?
- Liabilities as reported by NewAmsterdam Pharma Company N.V. Ordinary Shares.
Ask your AI about NewAmsterdam Pharma Company's liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude